Company Overview
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Recent Developments
- Dec 2025 Revenue of $29.33K (-82.3% YoY); net profit $-45.63M.
- Trailing 12 Months Year-on-year growth — revenue -82.3%.
- 5-Year Trend Long-term compounding — profit CAGR -18.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -82.31% |
Compounded Profit Growth
| 5 Years: | -18.26% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +165.93% |
| 6 Months: | +128.18% |
| 3 Months: | +26.90% |
| 1 Month: | +17.93% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)53.20 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -18.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IFRX InflaRx N.V. PHARMA | 2.17 | -3.74 | $319.79M | 0.00% | -107.93% | -38.52% | - | -18.26% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 39.43K | 23.83K | -33.93K | 0 | 0 |
| Cost of Revenue | - | 2.40M | 333 | 4.86M | 0 | 0 |
| Gross Profit | - | -2.36M | 23.50K | -4.89M | 0 | 0 |
| Operating Expenses | - | 10.58M | 9.50M | 7.96M | 7.21M | 7.00M |
| Operating Income | - | -12.94M | -9.48M | -12.86M | -7.21M | -7.00M |
| EBITDA | - | -14.32M | -12.13M | -10.53M | -5.49M | -10.49M |
| Interest Expense | - | 3.35K | 14.36K | 17.44K | 14.81K | 14.64K |
| Pretax Income | - | -14.44M | -12.25M | -10.64M | -5.59M | -10.60M |
| Tax Provision | - | 0 | 12.28K | 0 | 0 | 0 |
| Net Income | - | -14.42M | -12.26M | -10.64M | -5.59M | -10.65M |
| Diluted EPS | -0.13 | -0.21 | -0.18 | - | -0.08 | -0.09 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 63.09K | 165.79K | 29.33K |
| Cost of Revenue | 0 | 532.26K | 3.32M | 7.27M |
| Gross Profit | 0 | -469.17K | -3.15M | -7.24M |
| Operating Expenses | 32.24M | 44.13M | 49.75M | 41.02M |
| Operating Income | -32.24M | -44.59M | -52.91M | -48.26M |
| EBITDA | -28.84M | -42.06M | -45.55M | -45.16M |
| Interest Expense | 45.25K | 35.63K | 20.66K | 39.24K |
| Pretax Income | -29.48M | -42.67M | -46.06M | -45.62M |
| Tax Provision | 0 | 0 | 5.22K | 12.28K |
| Net Income | -29.48M | -42.67M | -46.06M | -45.63M |
| Diluted EPS | -0.67 | -0.78 | -0.78 | -0.68 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 102.40M | 120.21M | 76.02M | 55.22M |
| Current Assets | - | 97.41M | 109.47M | 71.66M | 53.63M |
| Cash & Equivalents | - | 16.27M | 12.77M | 18.38M | 16.02M |
| Inventory | - | 0 | 11.37M | 6.90M | 0 |
| Receivables | - | 1.43M | 3.79M | 1.74M | 1.43M |
| Total Liabilities | - | 14.05M | 17.63M | 14.60M | 13.66M |
| Current Liabilities | - | 13.03M | 16.84M | 14.17M | 12.98M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 1.36M | 1.12M | 805.09K | 897.92K |
| Total Equity | - | 88.35M | 102.58M | 61.42M | 41.56M |
| Shares Outstanding | - | 44.70M | 58.88M | 59.35M | 72.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -33.74M | -37.81M | -48.56M | -35.31M |
| Investing Cash Flow | 19.36M | -17.70M | 52.36M | 3.23M |
| Financing Cash Flow | 1.94M | 52.99M | 386.45K | 33.32M |
| Capital Expenditure | -162.39K | -81.10K | -46.87K | -115.69K |
| Free Cash Flow | -33.91M | -37.89M | -48.60M | -35.43M |
| Net Change in Cash | -12.45M | -2.52M | 4.19M | 1.24M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | -743.7% | -1,900.8% | -24,677.9% |
| Operating Margin % | - | -70,685.6% | -31,911.4% | -164,525.5% |
| Net Margin % | - | -67,630.7% | -27,785.0% | -155,582.1% |
| ROE % | -33.4% | -41.6% | -75.0% | -109.8% |
| ROCE % | -36.1% | -43.1% | -85.5% | -114.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 97.39% | 14.50M | $30.30M |
| 2 | FMR, LLC | 54.83% | 8.16M | $17.06M |
| 3 | Commodore Capital Lp | 49.03% | 7.30M | $15.26M |
| 4 | Spruce Street Capital LP | 35.95% | 5.35M | $11.19M |
| 5 | 683 Capital Management LLC | 34.02% | 5.07M | $10.59M |
| 6 | Farallon Capital Management LLC | 22.33% | 3.33M | $6.95M |
| 7 | Stempoint Capital LP | 21.68% | 3.23M | $6.75M |
| 8 | Great Point Partners LLC | 20.46% | 3.05M | $6.37M |
| 9 | Adar1 Capital Management, LLC | 20.15% | 3.00M | $6.27M |
| 10 | Montanova Capital LLC | - | 22.93M | $47.93M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IFRX
Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxOQU5EOXVSV0NQamNhOWJQblhkM0FSUEJNTDVoeDRTX2I0amxfMmJlRkVac3dIWkF0R1BHd3RPNXdFdzNjdGVHbXdxRHZNMGxyYVdwdU1uYVFFaS1YR2FESndqalZzSVNoeFZzMXlOWHBaTW4tbTJrclVNQVhoSnFHQ1lmX0J0eXc4M3I5T2…
IFRX Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9UME5tb2NWc2x6UkRqV0llWUdObVhEVU5ucGtmMW8wcjV1N2pmdlN3NmNwUG1KN29FaXM0YW5NRTFWQTFwYm5fMktOWm9rWi1SS0hSWndJR055aFdBeENuZTg3QmlTQXl0Mm1BUHhpT0tFWWRZRmhSOFhR?oc=5" target="_blank">IFR…
InflaRx N.V. SEC Filing (Aug 13, 2026) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNZXl1ZlpHcTRESnBJS3hfVnpobFBGeEpKSm1sN2ZwQzZzS0oxc05DUHVEZUdRdmNKNmZSajFORmpLQkJJQ1A3WmNZMTZKOS1yemxuSDZqQ2hETll6UFZTR1VXVDVuMXRGaVIxbGVyVllzS3pNSUZZSUVFT3gwNnNxYS1zdW9IWUQwVEwtc3…
IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi9gFBVV95cUxPdjZXMHVKSWU2SzlFUUpoOFZ6YXJkX2dxTjFiQUNrUVhLQ05ZZU5OMkQ2c2lycXlmSEtZdU43dXFDUUdLNW5BWmdFdFNrMHZwdms1ZUQ4MWhQTG5LMU9Xc2UyX1RVOTZrVHNuZzRGVmppLWZMMXNiUXJpUzBlaEl3T1B0aDZ1T1ZhbU5vZX…
INFLARX ($IFRX) Releases Q2 2026 Earnings | IFRX Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNTlhnRmRwVm1FMHFPUHBFQTdXbjNiY1ZiU1JwdDE3QV9LMmZRd243TmZIRlRsLXA3S1RrUWxPdzhrbUxPSFJ0dWRvdW4zcUdxd1lVMDdDV3FHNGpTb25fWl8wLThDeUdEbTg2UGFMRE5DamZZTXE0OVhzMDJoVXBPU1lBa3FlTWM?oc=5" …
IFRX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1xVkxQZFhad201bDVvdU9HNGZoNHk4M2d0ZHItemVGU3RQWHF2RzZQaVJ1V3UzVjFMbWh4TzVKUmZZeWsxYlE?oc=5" target="_blank">IFRX</a> <font color="#6f6f6f">Finviz</font>…
IFRX — Frequently Asked Questions
What is the current share price of InflaRx N.V. (IFRX)?
As of 2026-09-19 21:16 PDT, InflaRx N.V. (IFRX) trades at $2.17 on NasdaqGS. Its 52-week range is $0.82 to $2.74.
What is the market capitalisation of IFRX?
InflaRx N.V. (IFRX) has a market capitalisation of $319.79M on NasdaqGS.
What is the P/E ratio of IFRX?
IFRX trades at a trailing price-to-earnings (P/E) ratio of -3.74. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.81.
What is the return on equity (ROE) of IFRX?
IFRX has a return on equity (ROE) of -38.52%. Its return on capital employed (ROCE) is -107.93%.
Is IFRX a good stock to buy?
This page provides a data-driven analysis of InflaRx N.V. (IFRX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.